Pilaralisib (XL-147) is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, among others.
Molecular Weight:
541.02
Purity:
99.61%
CAS Number:
[934526-89-3]
Formula:
C25H25ClN6O4S
Target:
PI3K
T2365
* VAT and and shipping costs not included. Errors and price changes excepted